ChiCTR2600123542 版本V1.0 版本创建时间2026/04/27 17:36:10 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123542 

最近更新日期:

Date of Last Refreshed on:

2026-04-27 17:35:34 

注册时间:

Date of Registration:

2026-04-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

高原儿童生理及相关危重症循环系统超声图谱队列及智能诊断体系构建

Public title:

Ultrasound Atlas Cohort and Intelligent Diagnostic System for Circulatory System in High?Altitude Pediatric Physiology and Critical Illnesses: A Construction Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

高原儿童生理及相关危重症循环系统超声图谱队列及智能诊断体系构建

Scientific title:

Ultrasound Atlas Cohort and Intelligent Diagnostic System for Circulatory System in High?Altitude Pediatric Physiology and Critical Illnesses: A Construction Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

肖甜甜 

研究负责人:

巨容 

Applicant:

Xiao Tiantian  

Study leader:

Ju Rong 

申请注册联系人电话:

Applicant telephone:

+86 159 8229 4547

研究负责人电话:

Study leader's
telephone:

+86 180 8010 3629

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xiao13671814745@163.com

研究负责人电子邮件:

Study leader's E-mail:

Jurong123@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国四川省成都市青羊区日月大道1617号

研究负责人通讯地址:

中国四川省成都市青羊区日月大道1617号

Applicant address:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan, China

Study leader's address:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都市妇女儿童中心医院

Applicant's institution:

Chengdu Women's and Children's Center Hospital

研究负责人所在单位:

成都市妇女儿童中心医院

Affiliation of the Leader:

Chengdu Women's and Children's Center Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科研伦审2026(44)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

成都市妇女儿童中心医院伦理委员会

Name of the ethic committee:

Ethics Committee of Chengdu Women and Children's Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-03-31 00:00:00

伦理委员会联系人:

唐丽娟

Contact Name of the ethic committee:

Tang Lijuan

伦理委员会联系地址:

中国四川省成都市青羊区日月大道1617号

Contact Address of the ethic committee:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 6186 6015

伦理委员会联系人邮箱:

Contact email of the ethic committee:

lunliwyh@163.com

研究实施负责(组长)单位:

成都市妇女儿童中心医院

Primary sponsor:

Chengdu Women's and Children's Center Hospital

研究实施负责(组长)单位地址:

中国四川省成都市青羊区日月大道1617号

Primary sponsor's address:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都市妇女儿童中心医院

具体地址:

中国四川省成都市青羊区日月大道1617号

Institution
hospital:

Chengdu Women's and Children's Center Hospital

Address:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan,China

经费或物资来源:

西藏自治区科技计划项目(项目编号CGZH2025000523)资助

Source(s) of funding:

Supported by Science and Technology Projects of Xizang Autonomous Region, China (No. CGZH2025000523)

研究疾病:

健康新生儿;新生儿和儿童危重症疾病  

Target disease:

Healthy newborns;Neonatal and pediatric critical illnesses

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1.通过建立健康队列,获取循环超声参数,利用机器学习算法绘制高原健康新生儿循环生理指标超声图谱。 2.建立高原儿童/新生儿相关危重症(呼吸窘迫综合症、重症肺炎等)队列,获取临床信息及循环相关超声参数,利用相关性分析揭示循环超声指标在高原儿童相关危重症中的临床意义。 3.基于前述健康和危重症队列,搭建“临床文本-超声”的多模态数据平台,利用智能诊疗和辅助决策算法,构建高原儿童危重症的智能诊疗体系。  

Objectives of Study:

1. Establish a healthy cohort, acquire circulatory ultrasound parameters, and use machine learning algorithms to generate a reference atlas of circulatory physiological indicators for healthy neonates in high?altitude regions. 2. A cohort of critically ill neonates and children with high-altitude?related conditions (e.g., respiratory distress syndrome, severe pneumonia, etc.) is established to collect clinical data and circulatory ultrasound parameters. Correlation analysis is employed to elucidate the clinical significance of circulatory ultrasound indicators in pediatric critical illnesses at high altitude. 3. Based on the above healthy and critically ill cohorts, develop a multimodal data platform integrating clinical text and ultrasound data, and construct an intelligent diagnosis and treatment system for pediatric critical illnesses in high?altitude regions using intelligent diagnostic and decision?support algorithms.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.健康新生儿队列纳入标准: (1)联合西藏自治区内不同海拔的医院,前瞻性纳入低风险孕妇且妊娠期持续(> 3 个月)居住于海拔>=1500米分娩的单胎健康、出生胎龄 37-42周新生儿; (2)遵循伦理及知情同意原则。 2.危重儿队列纳入标准: (1)新生儿肺疾病及危重症(满足以下所有条件): 1)母亲孕期生活在海>=1500米 地区的时间超过 3 月; 2)诊断为呼吸窘迫综合征或需要呼吸机支持(有创)或新生儿脓毒症者(或新生儿败血症) 3)法定监护人知情同意。 (2)儿童肺疾病及危重症(满足以下所有条件): 1)年龄<=18 岁、生活在海拔>=1500米 地区时间超过 3 月 2)诊断为重症肺炎或脓毒症者; 3)法定监护人知情同意。

Inclusion criteria

1. Inclusion Criteria for Healthy Newborn Cohort (1) In collaboration with hospitals at different altitudes within the Tibet Autonomous Region, prospectively enroll healthy, singleton, term neonates (gestational age 37–42 weeks) born to low?risk pregnant women who have resided continuously (for more than 3 months) at an altitude of >=1500 m during pregnancy. (2) Adhere to the principles of ethics and informed consent. 2. Inclusion Criteria for Critically Ill Cohort (1) Neonatal Pulmonary Diseases and Critical Illnesses (all of the following criteria must be met): ??1) The mother resided at an altitude of >=1500m for more than 3 months during pregnancy. ??2) The neonate is diagnosed with respiratory distress syndrome (RDS), or requires invasive mechanical ventilation, or is diagnosed with neonatal sepsis. ??3) Informed consent is obtained from the legal guardian. (2) Pediatric Pulmonary Diseases and Critical Illnesses (all of the following criteria must be met): ??1) Age <=18 years, with residence at an altitude of >=1500m for more than 3 months. ??2) Diagnosed with severe pneumonia or sepsis. ??3) Informed consent is obtained from the legal guardian.

排除标准:

1. 法定监护人要求退出或 7 天内因心肺疾病入住新生儿科。 2. 可能影响生后过渡期的其他因素: (1)母孕期或分娩前非低风险(五色管理分类) (2)任何新生儿疾病。

Exclusion criteria:

1. The legal guardian requests withdrawal, or the neonate is admitted to the neonatology department due to cardiopulmonary disease within 7 days after birth. 2. Presence of other factors that may affect the postnatal transitional period, including: (1) Maternal non?low?risk status during pregnancy or prior to delivery (according to the five?color risk management classification); (2) Any neonatal disease

研究实施时间:

Study execute time:

From 2025-07-01 00:00:00 To 2028-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-01 00:00:00 To 2028-04-01 00:00:00

干预措施:

Interventions:

组别:

健康新生儿组

样本量:

500

Group:

Healthy newborns group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

危重症新生儿和儿童组

样本量:

359

Group:

Critically ill neonates and children group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

成都 

市(区县):

 

Country:

Cina

Province:

Sichuan

City:

单位(医院):

成都市妇女儿童中心医院 

单位级别:

三甲 

Institution
hospital:

Chengdu Women's and Children's Center Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

Cina

Province:

Chongqing

City:

单位(医院):

陆军军医大学陆军特色医学中心 

单位级别:

三甲 

Institution
hospital:

Army Medical Center of PLA

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

昆明医科大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Kunming Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

超声心动图血流动力学指标(包括右心面积变化分数、右心心输出量、左心射血分数、二/三尖瓣半环收缩位移、左心输出量、二/三尖瓣舒张早期血流速度、 二/三尖瓣舒张晚期血流速度 、PDA 大小/分流方向、右心射血时间、肺动脉加速时间等))

指标类型:

主要指标

Outcome:

Echocardiographic hemodynamic Indices(including RV FAC, RV CO, LVEF, MAPSE/TAPSE, LV CO, Mitral/Tricuspid early diastolic inflow velocity, Mitral/Tricuspid late diastolic inflow velocity , Patent ductus arteriosus size / Shunt direction, RVET, PAAT,etc.)

Type:

Primary indicator

测量时间点:

生后 6-12 小时、24-48 小时、3-5 天、28 天

测量方法:

超声

Measure time point of outcome:

6–12 hours, 24–48 hours, 3–5 days, and 28 days after birth

Measure method:

Ultrasound

指标中文名:

脑血流动力学指标(包括收缩期峰值速度、舒张末期速度、阻力指数和搏动指数等)

指标类型:

主要指标

Outcome:

Cerebral hemodynamic indices(including PSV, EDV,RI,PI,etc.)

Type:

Primary indicator

测量时间点:

生后 6-12 小时、24-48 小时、3-5 天、28 天

测量方法:

超声

Measure time point of outcome:

6–12 hours, 24–48 hours, 3–5 days, and 28 days after birth

Measure method:

Ultrasound

指标中文名:

肺超声(6分区法)

指标类型:

主要指标

Outcome:

Lung Ultrasound(six-region score)

Type:

Primary indicator

测量时间点:

生后 6-12 小时、24-48 小时、3-5 天、28 天

测量方法:

超声

Measure time point of outcome:

6–12 hours, 24–48 hours, 3–5 days, and 28 days after birth

Measure method:

Ultrasound

指标中文名:

肾、胃肠道等脏器功能指标(脏器灌注指标)

指标类型:

主要指标

Outcome:

Renal, gastrointestinal, and other organ function indicators((Organ perfusion parameters))

Type:

Primary indicator

测量时间点:

生后 6-12 小时、24-48 小时、3-5 天、28 天

测量方法:

Measure time point of outcome:

6–12 hours, 24–48 hours, 3–5 days, and 28 days after birth

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

脐带血

组织:

Sample Name:

umbilical cord blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

胎盘组织

组织:

Sample Name:

placental tissue

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

粪便和尿液

组织:

Sample Name:

stool and urine

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

痰液/肺泡灌洗液

组织:

Sample Name:

sputum/bronchoalveolar lavage fluid

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表 REDCap数据库或问卷星

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF REDCap (Research Electronic Data Capture) database or Wenjuanxing

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-04-27 17:35:34